RAD51 and B-cell chronic lymphocytic leukemia: In line with these results, the RAD51 inhibitor B02 also synergized with olaparib in stimulated CLL primary samples (Fig. 5b, right panel) and HG3WT and HG3-del(11q) ATMKO CRISPR/Cas9-edited cells (Supplementary Fig. S7d).